•Metabolic syndrome and type 2 diabetes mellitus increase risk of cognitive impairment and dementia
•Executive function decline likely worsens health management and hastens metabolic disease progression
•This association may be explained in part by elevated levels of glycated peptides, which have been implicated in the pathogenesis of cognitive aging and cognitive disease processes.
•Glycated peptides are formed from the non-enzymatic cross-linking of serum proteins with monosaccharides; hyperglycemia or even normal increases in blood glucose will increase rate of formation.
•Increased peptide glycation and the accumulation of advanced glycation end products have been linked to many complications of diabetes (vascular, amyloidosis, inflammation, changes in gene expression, etc.), but their role in cognitive dysfunction is not well-established; a vascular etiology is most likely
AIM: To determine if serum levels of glycated peptides predict 1) change in cognitive function over a 5-year period of time, and 2) cognitive outcomes at 5 years from baseline in older women.